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Revie w
The Cartwright (Yt) blood group system consists of two 
antigens, Yta and Ytb, that result from point mutations in the 
acetylcholinesterase gene on chromosome 7q. Yta is a high-
incidence antigen, whereas its antithetical antigen, Ytb, shows 
much lower incidence. Anti-Yta and anti-Ytb are relatively rare. 
Anti-Yta is more commonly found in individuals of Jewish descent. 
Cartwright antibodies are rarely clinically significant; however, 
cases of in vivo hemolysis have been reported, suggesting that 
clinical significance should be interpreted on a case-by-case 
basis. Immunohematology 2012;28:49–54.
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History
Anti-Yta and thus the Yta antigen of the Cartwright blood 
group system were first described in 1956 by Eaton and 
colleagues.1 This discovery in the early 1950s came on the heels 
of the identification of three other antibodies against high-
incidence antigens (anti-Tja, -Vel, and -U). This new antibody 
was noted to agglutinate the majority of red blood cells (RBCs) 
of whites and was independent of all other known blood group 
systems. The antibody was first identified in a woman with a 
history of four pregnancies complicated by severe hemorrhage 
at delivery. She received several units of blood after her last 
delivery. Several years later, she required more transfusions. 
RBC units were weakly incompatible with her serum by the 
indirect antiglobulin test (IAT). Blood samples from eight 
laboratory staff members were also tested with the patient’s 
serum and found to be incompatible. Transfusion was deferred 
until compatible blood could be obtained. The patient was 
discharged to home, and her hemoglobin level recovered 
without transfusion.
Serologic investigations performed on the patient’s serum 
against a panel of RBCs of known phenotype demonstrated 
no agglutination in saline or albumin, slight but easily 
dispersible agglutination with trypsin-treated cells, and no 
reactivity with papain-treated cells. Owing to the weak and 
variable reactivity, Eaton and colleagues1 decided to rule out 
a mixture of antibodies, and repeatedly adsorbed the serum 
with a number of strongly and weakly reacting cells. Six 
adsorptions were performed with equal volumes of strongly 
reacting cells at 37°C. After 1 hour, the antibody titer was 
reduced from between 32 and 128 to between 2 and 4. The 
sera after adsorption tested against a panel of cells indicated 
that only a single antibody was present. The antigen to which 
this antibody was reacting was provisionally named Yta. Eaton 
and colleagues1 assumed that the antithetical antigen in this 
system, if discovered, would be called Ytb. Having excluded the 
presence of more than one antibody, the researchers noted that 
the observed differing strengths of reactivity could represent a 
dosage effect, with weak reactors symbolizing heterozygotes. 
Forty-four members of the laboratory staff were tested. Of those 
44, 5 reacted weakly. If those 5 represented heterozygotes, it 
was calculated that a negative would be encountered in every 
250 to 300 random blood samples (0.348%). The goal of these 
initial investigations was to obtain compatible blood. A total 
of 1051 group O donors were tested with the patient’s serum 
at two dilutions, 1 in 4 and 1 in 8, by the IAT. Tests were 
interpreted by the same staff members and were graded as 
strong, weak, and intermediate. Four negatives were identified 
and confirmed by repeat testing. The incidence of negatives 
was calculated as 0.38 percent. Extensive serologic testing 
demonstrated the independence of this new blood group 
system from ABO, Rh, and MNS systems. Yta was identified 
on the RBCs of six infants at birth; reactivity was weaker than 
on adult cells. Further proof of this new blood group system 
was provided through the identification of additional cases of 
anti-Yta by Race and Sanger,2 Bergvalds and colleagues,3 and 
Dobbs.4 In 1963, Yta was demonstrated to be separate from the 
Lutheran blood group system by Allen et al.5 using a detailed 
family pedigree starting with a mother of six children who was 
homozygous for both Yta and Lua. Given the significant genetic 
recombination as evidenced by the varied phenotypes in the 
children, it was clear that Yt and Lu were not related. The same 
pedigree demonstrated Yt to be separate from the Rh system.
Giles identified and reported the expected antithetical 
antigen, Ytb, in 1964.6,7 The patient was known to have anti-
Fyb and an additional unidentified antibody. This antibody 
was isolated by adsorption and elution and tested against 
random blood samples. Nineteen of 229 samples demonstrated 
reactivity. Six known Yt(a–) RBC samples were tested against 
an eluate containing only the unknown antibody in the patient’s 
serum. All reacted positively, with presumptive identification 
of anti-Ytb, adding further evidence of the discovery of the 
antithetical antigen, Ytb. A second example of anti-Ytb was 
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presented by Ikin et al.8 in a case report of a patient with 
paroxysmal nocturnal hemoglobinuria (PNH) with aplastic 
bone marrow. He had been receiving six units of blood two or 
three times a year since 1957. This group found Ytb in about 8 
percent of random samples, and the incidence of individuals 
with the Yt(a+b–) phenotype was reported to be as high as 
91.4 percent. Given these statistics, it seemed likely that other 
cases of anti-Ytb may have passed unnoticed. In 1968, Wurzel 
and Haesler9 found another anti-Ytb in a 76-year-old man who 
had received many transfusions.
Nomenclature
The blood group system was named after the patient, 
Mrs. Cartwright, in whom it was first identified. Eaton and 
colleagues1 developed the system’s nomenclature by using the 
last letters of the patient’s first and last name (Y and T), since 
her initials, A and C, already represented well-known blood 
group antigens. They adopted the idea of using a superscript 
letter to denote individual antigens within the system, starting 
with Yta and assuming that the antithetical antigen in this 
system, if discovered, would be called Ytb. The nomenclature 
across various systems is denoted in Table 1.10–16
Genetics/Inheritance
The original cases of anti-Yta were identified in patients 
of Jewish ancestry. The National Blood Group Reference 
Laboratory in Jerusalem identified 14 patients of 4474 
referrals with anti-Yta, which was higher than expected based 
on prior European data. Once anti-Ytb became available, this 
group undertook a survey of Yt groups using both anti-Yta 
and anti-Ytb on Israeli Jews. They tested 264 blood samples 
selected at random from the population and found that Ytb 
and anti-Yta are relatively frequent among Israelis. These 
discoveries prompted further testing using the Yt system as 
a useful genetic marker in examining potential variability 
among different Jewish ethnic groups.17–19 This same Israeli 
group looked at 1683 blood samples from Israeli Jews, Arabs, 
and Druse to determine the incidence of the Yt blood group 
phenotype and allelic frequencies. These populations had an 
overall incidence of the Yt(b+) phenotype ranging from 24 to 
26 percent, versus a general European incidence of 8 percent. 
A null phenotype, Yt(a–b–), was not identified. These findings 
suggested that if blood group antibodies against a high-
incidence antigen were detected in an individual of Jewish, 
Arab, or Druse descent, the probability of anti-Yta would be 
high. Few ethnic groups have been tested for the incidence of 
Yt blood group system phenotypes and for allelic frequencies; 
however, individuals of Jewish descent and other Mid-Eastern 
ethnicities tended to have a lower incidence of Yta and a higher 
incidence of Ytb. Ytb was not identified in a random sampling 
of 70 Japanese individuals.17 The incidence of the Yt(a+b–) 
phenotype in American blacks and white Canadians was 
found to be essentially the same as determined in studies of 
Europeans, as reported by Wurtzel and colleagues20 in 1968 
and Lewis and colleagues21 in 1987. Overall, Yta occurs in 
approximately 99.7 percent of American and European blood 
donors, whereas the antithetical Ytb is found in 8.1 percent 
of these donors. Yt(a–b–) appears to be transient, and a true 
inherited Yt(a–b–) phenotype would be extremely rare.22 The 
percent occurrences of general phenotypes in Americans and 
Europeans are summarized in Table 2.23
Molecular Basis
Even after the Cartwright antigen system was well 
characterized serologically, the chromosomal location 
was not known until 1991. In 1987, Lewis et al.21 looked at 
linkage between Yt and 42 chromosomally assigned loci, but 
relationships were not clear. By 1989, Yt was believed to be 
loosely linked to the Kell system.24 Linkage was shown to 
occur between the Yt and Kell loci at a recombination fraction 
of 28 percent. So when Kell was provisionally assigned to 
chromosome 7q, the placement of Yt seemed to be the next 
step. Based on their previous work with loci on chromosome 
Table 1. Nomenclature





number Traditional ISBT ISGN
Yt or 
Cartwright
011 Yt YT Yt YT ACHE
Yta YT1 011.001
Ytb YT2 011.002
ISBT = International Society of Blood Transfusion
ISGN = International System for Gene Nomenclature
Table 2. Yt Phenotypes
% Bloods Reacting With






IMMUnoHeMAtoLoGY, Volume 28, number 2, 2012 51
Yt blood group system review 
7, Zelinski and colleagues were able to demonstrate linkage 
to COL1A2 and D7S13 genotypes through paternal meiosis. 
Because it showed no recombination, Yt was provisionally 
assigned to chromosome 7, particularly within 7q22.1–
q22.3.25–28 Further studies of chromosome 7 also localized 
acetylcholinesterase (AChE) to 7q22. AChE plays a crucial 
role in cholinergic neurotransmission, and is found in the 
RBC membrane, where its function remains largely unknown. 
AChE undergoes extensive posttranslational modification, 
which may leave room for genetic variability.29–32 A study by 
Spring et al.33 provided evidence that Yt blood group antigens 
are located on erythrocyte AChE. This study identified 
immune precipitates of human anti-Yta and -Ytb of the same 
molecular weight as AChE from radioiodinated erythrocytes 
of appropriate Yt phenotype. The immune precipitates 
obtained with anti-Yta and -Ytb contained AChE activity. 
These results indicated that the Yt antigens were derived 
from an inherited polymorphism of AChE, and in addition to 
Zelinski’s provisional assignment of Yt blood group locus to 
chromosome 7, gave provisional identification of the location 
of the ACHE gene. Further corroborating the link between Yt 
and AChE, Bartels et al.34 discovered that the Yt blood group 
polymorphism is caused by point mutations in the ACHE 
gene. Further genetic characterization demonstrated that the 
YT(ACHE) gene consists of six exons distributed over 2.2 kbp 
of genomic DNA. The molecular basis of the Yt antigens is 
summarized in Table 3.11
Biochemistry
Early studies of the Kell blood group antigen system 
led to some biochemical parallels between this system and 
the Cartwright system. Studies of the effect of dithiothreitol 
(DTT) on Kell and other RBC antigens led to the discovery 
that all Kell blood group antigens as well as Yta are completely 
denatured after treatment with DTT. Other sulfhydryl 
reagents did not result in Yta denaturation. Yta was denatured 
within the same DTT concentration range as Kell, which 
led Branch and colleagues35 to speculate that a biochemical 
relationship existed between the two systems. They concluded 
that Yta requires at least one disulfide bond for maintenance of 
antigen integrity, implying a protein backbone. These findings 
paved the way for further biochemical characterization of the 
Cartwright antigen system.36,37 The protein structure of the 
antigens within the Cartwright system helps to explain their 
serologic properties. Effects of enzymes and chemicals on Yt 
antigens are summarized in Table 4.11,38
Additionally, Levene and Harel39 noted that 2-amino-
ethylisothiouronium (AET)-treated RBCs, which their 
laboratory used to detect antibodies to high-incidence antigens, 
may be helpful in the identification of Cartwright antibodies. 
Because disulfide bonds are a requirement for Cartwright 
antigen integrity, AET can reduce these bonds and eliminate 
reactivity.
In tandem with the molecular studies of the Cartwright 
antigen system, once a protein backbone was suspected, the 
study of patients with PNH led to the discovery that the Yt 
antigens likely resided on a phosphatidylinositol (PI)-anchored 
protein, as the complement-sensitive (PNH III) erythrocytes 
of these patients failed to express these antigens. However, 
the relatively normal constituent of complement-insensitive 
erythrocytes from the same patients expresses these antigens 
normally. Other high-incidence antigens showed varying 
levels of reactivity.40,41 Human RBCs express a wide variety 
of PI-anchored proteins, including decay accelerating factor 
(DAF; CD55), membrane inhibitor of reactive lysis (MIRL; 
CD59), lymphocyte function associated antigen-3 (LFA-3; 
CD58), AChE, oxidized nicotinamide adenine dinucleotide 
(NAD+) glycohydrolase, JMH protein (p76), and others. 
DAF is known to bear the Cromer blood group antigens. A 
study in 1993 by Rao and colleagues22 demonstrated that Yta 
resides on erythrocytes’ AChE. This study used RBCs from 
an individual with a previously uncharacterized Yt(a–b–) 
phenotype as well as normal Yt(a+) cells to serologically and 
Table 3. Molecular basis of the Yt antigens
Yta Ytb
Amino acid His 353 Asn 353
Nucleotide C at bp 1057 in exon 2 A at bp 1057 in exon 2
Additional 
features
Nucleotide at position 
1431 C>T in exon 3 also 
differentiates Yta from 
Ytb but does not alter the 
encoded amino acid.  
A second silent mutation in 
exon 5 does not correlate 
with the Yt polymorphism.
Nucleotide at position 
1431 C>T in exon 3 also 
differentiates Yta from 
Ytb, but does not alter the 
amino acid. A second silent 
mutation in exon 5 does  
not correlate with the  
Yt polymorphism.
Table 4. Effects of enzymes and chemicals on Yt antigens
Enzyme/chemical Yta Ytb





DTT 200 mM/50 mM Sensitive/weakened Sensitive/weakened
Acid Resistant Presumed resistant
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biochemically evaluate the relationship between Yta and PI-
linked erythrocyte proteins. Their work demonstrated that 
the Yt(a–b–) RBCs expressed normal amounts of all PI-linked 
proteins except for AChE, which added further proof of the 
Yt blood group system stemming from AChE.40 Yta is weakly 
expressed on cord RBCs, whereas Ytb shows the same level of 
expression on cord cells as on adult RBCs.11–13
In the late 1970s and early 1980s, a number of studies 
were undertaken to investigate the presence or absence 
of RBC antigens on various white blood cell fractions. 
Historically, there was no consensus in the literature regarding 
this topic.42,43 In 1984, using flow cytometry, Dunstan44 
demonstrated that Yta was not detected on lymphocytes, 
monocytes, or neutrophils.
Antibodies
The discovery of the Yt blood group system was dependent 
on the identification of the antibodies directed against the 
antigens within the system. There are only two antigens in 
the Yt blood group system, Yta and Ytb, and therefore only two 
possible antibodies. Both anti-Yta and -Ytb are of the IgG class 
and are optimally detected at the IAT phase. The incidence 
of the Yt (a–) phenotype, and hence anti-Yta, is higher in 
populations of Jewish descent. The first cases of anti-Yta were 
found in Jewish women who were sensitized by pregnancy or 
blood transfusion.
Eaton et al.1 were the first to describe anti-Yta and hence 
Yta. Race and Sanger2 reported three additional cases of anti-
Yta in their book Blood Groups in Man in 1962. An additional 
case of anti-Yta was reported by Bergvalds and colleagues3 in 
1965. Their case was that of a Jewish woman who presented 
for induction of labor at 40 weeks’ gestation. She had one 
previous pregnancy in which no antibodies were identified. 
She had no history of abortions, miscarriages, or previous 
blood transfusions. Late in her pregnancy, she was found to 
have a rising anti-D titer and a second unidentified antibody. 
After serologic investigation pointed to anti-Yta, a blood sample 
was sent to the Blood Group Reference Laboratory in London, 
England, where the presence of anti-Yta was confirmed. 
Additionally, the patient’s RBCs were tested against anti-Ytb, 
demonstrating that her phenotype was Yt(a–b+) as expected.
In 1968, Dobbs et al.4 reported clinical experience in 
three cases of anti-Yta. Over 3 years this group identified anti-
Yta in three patients: two were pregnant Jewish women with 
no evidence of hemolytic disease of the newborn (HDN); the 
third was a Jewish male patient with pure RBC aplasia who 
had been sensitized by multiple transfusions. Given the rarity 
of Yt(a–) blood and the severity of his anemia, this patient was 
transfused with several units of Yt(a+) blood with no evidence 
of untoward reaction. Chromium RBC survival studies were 
performed using an aliquot of transfused incompatible Yt(a+) 
blood. The study showed a RBC half-life of 30 days (normal 
is 27 to 30 days), so it appeared that this incompatibility had 
no effect on RBC survival in this patient. The patient required 
numerous transfusions and eventually underwent splenectomy 
and a regimen of steroids.
Clinical Significance
The clinical significance of Cartwright system antibodies 
is debatable. There are two main laboratory diagnostic tests 
to assess clinical significance: the monocyte monolayer assay 
(MMA), which is used in vitro, and the 51chromium labeling 
study, used in vivo.45,46 Most data regarding the clinical 
significance of these antibodies have been anecdotal through 
case studies. Despite evidence that anti-Yta and -Ytb are capable 
of crossing the placenta, their presence does not necessarily 
result in HDN, which may in part be explained by the fact that 
Yta generally shows weak expression on cord blood cells. Anti-
Yta does not generally cause transfusion reactions; however, 
moderate delayed reactions have been reported. The first 
evidence of clinical significance of anti-Yta came from Bettigole 
et al.47 Their group demonstrated rapid in vivo destruction of 
Yt(a+) RBCs in a patient with anti-Yta. They conducted an in 
vivo RBC survival study by transfusing 10 mL of chromium-
tagged Yt(a+) RBCs. The half-life of the transfused cells at 12 
minutes was estimated to be 3 days. Only about 13 percent 
of the original radioactivity was detected in vivo, despite 91 
percent effectiveness of chromium labeling in vitro. Several 
years later, Göbel et al.48 and Ballas and Sherwood49 identified 
additional examples of anti-Yta with rapid in vivo destruction 
of Yt(a+) RBCs.
Although chromium studies50,51 are useful, some 
antibodies have demonstrated a change in perceived clinical 
significance as detected with long-term chromium-labeling 
studies. AuBuchon and colleagues52 described an anti-Yta that 
initially did not appear to decrease RBC survival; however, 12 
weeks after transfusion of Yt(a+) RBCs, the alloantibody was 
characterized as IgG1 and repeat radiolabeled RBC survival 
studies demonstrated significant shortening of RBC lifespan 
as followed for 7 days. This particular case demonstrated 
a two-component survival curve in which initial rapid 
destruction is followed by slower removal of remaining cells. 
The authors attribute this to uneven antigen distribution, 
exhaustion of antibody, effect of RBC age, or blockade of 
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macrophage receptors for the complement system. Previous 
reports suggested the homogeneity of the Yt blood group 
system. However, an allogeneic anti-Yta in a Yt(a+) individual 
was reported by Mazzi et al.53 Both parents of the patient typed 
as Yt(a+). The patient’s serum was adsorbed with his father’s 
RBCs. Subsequently, the patient’s serum was tested with his 
mother’s RBCs, giving a positive reaction. Although all three 
parties tested Yt(a+), this pattern of reactivity suggests that a 
variant Yta was present in the propositus and his father that 
was distinct from the normal Yta found in the mother. Overall, 
recommendations for management of patients with anti-Yta 
must be based on the individual case. A 14-month study of 
five such patients conducted by Mohandas and colleagues54 
suggested considerable variability in these patients’ tolerance 
of Yt(a+) RBC transfusions. 
Little has been reported about the clinical significance of 
anti-Ytb. Ytb is expressed normally on cord blood cells; however, 
little is known about anti-Ytb in pregnancy, and therefore its 
potential to cause HDN is unknown. Generally, anti-Ytb is not 
believed to cause transfusion reactions. However, Levy et al.55 
both performed 51chromium-labeling studies in vivo and used 
MMA studies as an in vitro estimate of clinical significance. 
Their study found slightly abnormal MMA results and 
evidence of decreased RBC survival as measured by the 
51chromium-labeling study. This finding was similar to that 
reported by Baldwin et al.,56 which examined RBC antibodies 
of questionable clinical significance (anti-McCa, -JMH, -Kna, 
and -Hy).
In summary, the Cartwright blood group system is a small 
system that demonstrates interesting demographic patterns. 
The expression of Yt antigens is dependent on intact AChE 
and a PI backbone. Although antibodies to this system are 
generally considered clinically insignificant, case reports have 
demonstrated decreased RBC survival. It would be advisable to 
consider the clinical circumstances surrounding each case of 
anti-Yta or -Ytb in making a judgment on the clinical significance 
of the antibody. In emergency or urgent transfusion, most 
patients receiving Yt-incompatible blood have fared well; 
however, the various case reports discussed previously suggest 
that some cases have demonstrated decreased cell survival 
such that Yt-compatible blood would be preferable.
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